American Society for Microbiology, Journal of Clinical Microbiology, 5(58), 2020
DOI: 10.1128/jcm.00077-20
Full text: Download
Serological testing for nasopharyngeal carcinoma (NPC) has recently been reinvigorated by the implementation of novel Epstein-Barr virus (EBV)-specific IgA and IgG antibodies from a proteome array. Although proteome arrays are well suited for comprehensive antigen selection, they are not applicable for large-scale studies. We adapted a 13-marker EBV antigen signature for NPC risk identified by proteome arrays to multiplex serology to establish an assay for large-scale studies. Taiwanese NPC cases ( n = 175) and matched controls ( n = 175) were used for assay validation.